



# Phenotype Phebruary kickoff



# Looking back at Phenotype Phebruary 2022

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
		1  Type 2 Diabetes Mellitus (Patrick Ryan)	2  Type 1 Diabetes Mellitus (Ryan)	3  Acute Flaccid Paralysis (Ryan)	4  Multiple Myeloma (Ryan)	5  Adrenomedullary Pheochromocytoma (Ryan)
6  Hemorrhagic Stroke (Ryan)	7  Neutropenia (Ryan)	8  Kidney Stones (Ryan)	9  Dietary Lactose Intolerance	10  Systemic Lupus Erythematosus (Liam Bennett)	11  Scurvy (Thomas)	12  Parkinson's Disease (Liam Hill)
13  Adrenocortical Dysplasia Hypocortisolism (Ryan)	14  Hypertension (Jonathan Ross)	15  Acute Myocardial Infarction (Ryan)	16  Heart Failure (Ryan)	17  Cardiomyopathy (Ryan)	18  Multiple Sclerosis (Thomas)	19  Type 2 Diabetes Mellitus (Liam Hill)
20  Pulmonary Hypertension (Liam Hill)	21  Prostate Cancer (Liam Hill)	22  HIV (Ryan Bennett)	23  Hypothyroidism (Liam Hill)	24  Anxiety (Liam Hill)	25  Depression (Ryan Bennett)	26  Non-Small Cell Lung Cancer (Liam Hill)
27  Drug Induced Liver Injury (Liam Hill)	28  Gout (Liam Hill)	Bonni  Acute Kidney Failure (Liam Hill)	 Acute Kidney Failure (Liam Hill)			

<https://www.ohdsi.org/phenotype-phebruary/>



🌐 When poll is active, respond at **PollEv.com/patrickryan800**


# What do you want to see accomplished during Phenotype Phebruary 2023?

Top

No responses received yet. They will appear here...




# Common data model can enable standardized analytics across a distributed data network







# Engineering open science systems that build trust into the real-world evidence generation and dissemination process





# OHDSI's definition of 'cohort'

Cohort = a set of persons who satisfy one or more inclusion criteria for a duration of time

Cohort era = a continuous period during which a person has satisfied a cohort's inclusion criteria

Cohort definition = the specification for how to identify a cohort

---



# Questions to answer when defining a cohort

- What event(s) let you enter the cohort?
- What inclusion criteria are applied to those events?
- For each event, how long do you satisfy the inclusion criteria?
- How should events be combined into cohort eras?






# Concept Set Expressions

- Concept Set = logical expression to represent a list of concepts in the OHDSI vocabularies
  - List of 1 or more concepts
  - optional operators for each concept in list:
    - Descendants = uses CONCEPT\_ANCESTOR to identify standard concepts which have descendant ancestral relationship with selected concepts
    - Exclude = remove concept (and optionally descendants) from list
    - Mapped = use CONCEPT\_RELATIONSHIP to materialize non-standard concepts for all included concepts
- A conceptset expression can be materialized into a list of concepts using any instance of the OHDSI vocabularies
  - JSON expression executed via webAPI into standard SQL query



# A phenotype development and evaluation workflow





# OHDSI open-source community tools to support phenotype development and evaluation process

## Phenotype definition tools:

- ATLAS
  - Concept set expressions – with recommendations from PHOEBE2.0
  - Cohort Definitions – to design a rule-based cohort definition
  - Profiles – to review individual cases
- CapR - cohort definition application programming in R, to design rule-based cohort definitions consistent with CIRCE JSON specifications
- APHRODITE - to develop a probabilistic phenotype by training a prediction model using noisy labels

## Phenotype evaluation tools:

- CohortExplorer – to review individual cases
- CohortDiagnostics – to evaluate phenotype algorithms using population-level characterization to identify sensitivity/specificity errors and index date misspecification
- PheValuator - to evaluate a phenotype algorithm (estimate sensitivity/specificity/PPV) by training a prediction model and creating a probabilistic reference standard

## Phenotype Library



## 2. Classification and Diagnosis of Diabetes: *Standards of Medical Care in Diabetes—2021*

American Diabetes Association

*Diabetes Care* 2021;44(Suppl. 1):S15–S33 | <https://doi.org/10.2337/dc21-S002>

### CLASSIFICATION

Diabetes can be classified into the following general categories:

1. Type 1 diabetes (due to autoimmune  $\beta$ -cell destruction, usually leading to absolute insulin deficiency, including latent autoimmune diabetes of adulthood)
2. Type 2 diabetes (due to a progressive loss of adequate  $\beta$ -cell insulin secretion frequently on the background of insulin resistance)
3. Specific types of diabetes due to other causes, e.g., monogenic diabetes syndromes (such as neonatal diabetes and maturity-onset diabetes of the young), diseases of the exocrine pancreas (such as cystic fibrosis and pancreatitis), and drug- or chemical-induced diabetes (such as with glucocorticoid use, in the treatment of HIV/AIDS, or after organ transplantation)
4. Gestational diabetes mellitus (diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt diabetes prior to gestation)

**Table 2.2—Criteria for the diagnosis of diabetes**

FPG  $\geq 126$  mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.\*

OR

2-h PG  $\geq 200$  mg/dL (11.1 mmol/L) during OGTT. The test should be performed as described by WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.\*

OR

A1C  $\geq 6.5\%$  (48 mmol/mol). The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.\*

OR

In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose  $\geq 200$  mg/dL (11.1 mmol/L).

DCCT, Diabetes Control and Complications Trial; FPG, fasting plasma glucose; OGTT, oral glucose tolerance test; WHO, World Health Organization; 2-h PG, 2-h plasma glucose. \*In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.



# Creating T2DM definition(s) in ATLAS

ATLAS

Home

Data Sources

Search

Concept Sets

Cohort Definitions

Characterizations

Cohort Pathways

Incidence Rates

Profiles

Estimation

Prediction

Jobs

Configuration

Feedback

English

rao@ohdsi.org

Cohort #90

created by rao@ohdsi.org on 2022-01-31 19:07, modified by rao@ohdsi.org on 2022-01-31 19:07

[PhenotypePhebruary][T2DM] Persons with new type 2 diabetes mellitus at first dx rx or lab

Definition | Concept Sets | Generation | Samples | Reporting | Export | Versions | Messages 5

Enter a cohort definition description here

Cohort Entry Events

Events having any of the following criteria:

a condition occurrence of Type 2 diabetes mellitus (diabet...

+ Add attribute...

Delete Criteria

a drug exposure of Drugs for diabetes except insulin

+ Add attribute...

Delete Criteria

a measurement of Hemoglobin A1c (HbA1c) meas...

+ Add attribute...

Delete Criteria

with value as number Between 6.5 and 30

Unit is: percent Add Import

a measurement of Hemoglobin A1c (HbA1c) meas...

+ Add attribute...

Delete Criteria

with value as number Between 48 and 99

Unit is: millimole per mole Add Import

with continuous observation of at least 0 days before and 0 days after event index date

Limit initial events to: earliest event per person.

Restrict initial events

Inclusion Criteria

New inclusion criteria

no Type 1 diabetes mellitus diagnosis on or prior to T2DM

Copy Delete

1. has 365d prior observation

2. no Type 1 diabetes mellitus diagnosis on or prior to T2DM

3. no secondary diabetes diagnosis on or prior to T2DM

4. has at least one diagnosis of T2DM on or within 365d of index date

enter an inclusion rule description

having all of the following criteria:

with exactly 0 using all occurrences of:

a condition occurrence of Type 1 diabetes mellitus

+ Add attribute...

Delete Criteria

+ Add criteria to group...

Apache 2.0

open source software

provided by


OHDSI

join the journey





# Evaluating T2DM definitions using CohortDiagnostics






# Four Weeks. Four Debates. 10 Completed phenotypes

Stagger  
Focused  
Harden  
Complete  
Make useful

Debates











# OHDSI Collaboration Opportunity Spotlight



**ICPE 2023**

**August 23 - 27**

**HALIFAX, NOVA SCOTIA, CANADA**  
HALIFAX CONVENTION CENTRE

**ispe**

**pharmacoepi.org**  
**#ICPE23 | @IntPharmacoEpi**

---

**ICPE 2023 Call for Abstracts**  
**Submission Deadline: February 13, 2023**

---

**Abstract submissions for the 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2023) are now being accepted online**

**Call for Abstracts**  
ICPE 2023 will be a live event held at the Halifax Convention Centre, Halifax, Nova Scotia, Canada, August 23-27, 2023. Virtual presentations are not permitted for the event; all presentations must be delivered in person. If you submit an abstract, it is with the intention that you will physically attend the conference to present it.

The ICPE 2023 is a unique forum for the exchange of scientific information from the fields of pharmacoepidemiology and therapeutic risk management among those in the pharmaceutical industry, government, academia, service

<https://www.pharmacoepi.org/meetings/annual-conference/>